Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension

Vascular Health and Risk Management

Volumn 8, Issue 1, 2012, Pages 381-387

  Shuster, Jerrica E ^a,b   Bleske, Barry E ^a,b   Dorsch, Michael P ^a,b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Azilsartan; Chlorthalidone; Combination; Hypertension

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZILSARTAN; AZILSARTAN MEDOXOMIL PLUS CHLORTALIDONE; CHLORTALIDONE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; IRBESARTAN; LOSARTAN; MEPIRODIPINE; OLMESARTAN; PLACEBO; TELMISARTAN; VALSARTAN; 2 ETHOXY 1 ((2' (5 OXO 2,5 DIHYDRO 1,2,4 OXADIAZOL 3 YL) BIPHENYL 4 YL)METHYL) 1H BENZIMIDAZOLE 7 CARBOXYLIC ACID; 2-ETHOXY-1-((2'-(5-OXO-2,5-DIHYDRO-1,2,4-OXADIAZOL-3-YL)-BIPHENYL-4-YL)METHYL)-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; DIURETIC AGENT; OXADIAZOLE DERIVATIVE;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; COMPARATIVE EFFECTIVENESS; CREATININE BLOOD LEVEL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; HYPOKALEMIA; MONOTHERAPY; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; CHLORTHALIDONE; DIURETICS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; OXADIAZOLES; TREATMENT OUTCOME;

EID: 84867670415     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S22583     Document Type: Review

References (29)

1. Roger V, Go A, Lloyd-Jones D. Heart disease and stroke statistics- 2011 update: a report from the american heart association. Circulation. 2011;123:e18-e209.
2. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
3. Dahlöf B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
4. Cheung BM, Lau CP, Kumana CR. Combination therapy for hypertension. Hong Kong Med J. 2003;9(3):224-226.
5. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-felodipine ER factorial study group. Am J Cardiol. 1997;79(4):431-435.
6. Langtry HD, McClellan KJ. Valsartan/hydrochlorothiazide. Drugs. 1999;57(5):751-755; discussion 756-758.
7. Drugs.com. Top 200 drugs for 2010. Available from: http://www.drugs.com/top200_units.html. Accessed December 13, 2011.
8. Cushman W, Ford C, Cutler J. Success and predictors of blood pressure control in diverse north american settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393-404.
9. Goncalves A, Fontes M, Klussmann E, et al. Spinophilin regulates central angiotensin II-mediated effect on blood pressure. J Mol Med. 2011;89:1219-1229
10. Chalmers J, Arima H. Management of hypertension: evidence from the blood pressure lowering treatment trialists' collaboration and from major clinical trials. Pol Arch Med Wewn. 2009;119(6):373-380.
11. Edarbi(azilsartan medoxomil) [Package Insert] Deerfield, IL. Takeda Pharmaceuticals America, Inc; 2011.
12. Ojima M, Igata H, Tanaka M. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. JPET. 2011;336:801-808.
13. Bakris G, Sica D, Weber M. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens. 2011;13:81-88.
14. White W, Weber M, Sica D. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57:413-420.
15. Clinicaltrials.gov. Efficacy and safety of azilsartan medoxomil co-administered with chlorthalidone in participants with essential hypertension. Study NCT00591773. Available from: http://clinicaltrials.gov/ct2/show/NCT00591773?term=NCT00591773&rank=1. Accessed December 13, 2011.
16. American Society of Hypertension. Twenty-Sixth Annual Scientific Meeting and Exposition [featured posters, poster 182]. J Clin Hypertens. 2011;13(S1):A12-A163. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2011.00459.x/abstract. Accessed January 2011.
17. American Society of Hypertension. Twenty-Sixth Annual Scientific Meeting and Exposition [featured posters, poster 162]. J Clin Hypertens. 2011;13(S1):A12-A163 Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2011.00459.x/abstract. Accessed January 2011.
18. Carter B, Ernst M, Cohen J. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43:4-9.
19. Flack J, Sica D, Nesbitt S. Chlorthalidone versus hydrochlorothiazide as a preferred diuretic: is there a verdict yet? Hypertension. 2011;57:665-666.
20. Five-year findings of the hypertension detection and follow-up program. I. reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979;242(23):2562-2571.
21. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention trial. Circulation. 1990;82(5):1616-1628.
22. Dorsch M, Gillespie B, Erikson S. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689-694.
23. Ernst M, Carter B, Goerdt C. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352-358.
24. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. the international verapamil-trandolapril study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-2816.
25. Dahlof B, Sever P, Poulter N, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiaizde as required in the Ango-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
26. Parati G, Giglio A, Lonati L. Effectiveness of barnidipine 10 or 20 mg plus losartan 50-mg combination versus losartan 100-mg monotherapy in patients with essential hypertension not controlled by losartan 50-mg monotherapy: a 12-week, multicenter, randomized, open-label, parallel-group study. Clin Ther. 2010;32:1270-1284.
27. Brown M, McInnes G, Papst C. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomized, parallel-group trial. Lancet. 2011;377:312-320.
28. Julius A, Kjeldsen S, Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
29. Corrao G, Nicotra F, Parodi A, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension. 2011;58(4):566-572.